Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Ting-Ting Yang1,2,3, Wei-Hao Chen1,2,3, Yan-Min Zhao1,2,3, Hua-Rui Fu1,2,3, He Huang1,2,3 and Ji-Min Shi1,2,3*

1 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 2 Institute of Hematology, Zhejiang University, Hangzhou, China, 3 Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China

Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor. Our report supports the efficacy of bruton tyrosine kinase inhibitor zanubrutinib in the treatment of CNS-PTLD, which provides a new therapeutic option.

Keywords: hematopoietic stem cell transplantation, EBV-negative, posttransplant lymphoproliferative disorder, lymphoma, zanubrutinib

INTRODUCTION

Post-transplantation lymphoproliferative disorder (PTLD) is a spectrum of unregulated lymphoid expansion ranging from polyclonal hyperplasia to monoclonal malignant lymphoma, which normally presents with nonspecific signs such as prolonged fever and lymphadenopathy (1). Most PTLDs originate from B cells, associated with Epstein-Barr virus (EBV) reactivation. Compared with PTLD in solid organ transplantation, PTLD after hematopoietic stem-cell transplantation (HSCT) is characteristic of high invasion, early dissemination and high mortality. Currently, there is no consensus regarding the treatment of PTLD.

CASE PRESENTATION

A 39-year-old Chinese man was diagnosed with BCR-ABL-positive acute lymphoblastic leukemia in November 2018. He was treated with 8 cycles of chemotherapy combined with imatinib, resulting in complete remission (CR). He received haploidentical hematopoietic stem cell transplantation (HSCT) from his daughter on September 25, 2019 during the first CR under a myeloablative conditioning regimen (cytarabine, busulfan, cyclophosphamide, methyl-N-2-chloroethyl-N-cyclohexyl-N-nitrosourea, and anti-thymocyte globulin). Prophylaxis against graft-versus-host
The distribution of T-cell subsets was examined: CD3+ T-cell count was 69 cells/μL and CD4+ T-cell count was 2 cells/μL, indicating that the patient was in a state of immunodeficiency. Systemic GVHD was not observed in the patient. Empirical treatment against Toxoplasma infection was implemented for 2 weeks but was ineffective. His clinical condition progressed on day +244 with grade II right-sided muscle strength, recurrent seizures, urinary incontinence, lethargy, memory loss, and transient consciousness disturbance. MRI was repeated, which revealed further enlargement of the lesion in the left thalamus, with a maximum diameter of approximately 53 mm (Figure 1B). We performed magnetic resonance spectroscopy (MRS), which depicted significant elevated lipid (Lip) and choline compounds (Cho) peaks, suggestive of lymphoma (Figures 2A, B). Brain biopsy, which was performed to confirm the diagnosis, identified monomorphic diffuse large B-cell lymphoma with EBV infection. The tumor cells stained positive for CD19, CD20, Bcl-2 (approximately 100%), PAX-5, c-myc (approximately 25%), CD79a, and CD43 (Figures 3A–C). The results of EBV-encoded RNA in situ hybridization were positive (Figure 3D). Lung CT, abdominal B-ultrasound examination and bone marrow biopsy showed no evidence of systemic PTLD. Positron emission tomography–computed tomography (PET/CT) was not performed considering that the patient was critical with unstable conditions at that time. Based on these findings, the diagnosis of EBV-PTLD in central nervous system was made.

Thus, CsA administration (50mg daily) was discontinued at the diagnosis of PTLD on day +250. A single dose of rituximab (375 mg/m²) was administrated on day +252, followed by high-dose methotrexate (MTX, 6 g) on day +256. After MTX+rituximab, his consciousness improved and the seizure disappeared, although he still had a headache with a numerical rating scale (NRS) score of 3. Brain MRI indicated a reduction in lesion size, with the longest diameter of 36mm (Figure 1C). Serum EBV-DNA load decreased to 2 log₁₀ within three weeks after administration of chemotherapy. The response to MTX-rituximab was stable disease. During the treatment of MTX-rituximab, the WBC and platelet counts decreased to a minimum of 0.9×10⁹/L and 28×10⁹/L, respectively. The patient also developed pulmonary infection. Considering that the patient’s inability to tolerate chemotherapy, whole-brain radiotherapy (WBRT) was implemented on day +280 (30 times, total dose of 30 Gy) for 47 days. During radiotherapy, the platelet and white blood cell (WBC) counts decreased to a minimum of 34×10⁹/L and 0.9×10⁹/L, respectively, but gradually recovered to normal. At the end of radiotherapy, his headaches were alleviated (NRS score=2) and the language impairment and dyskinesia also recovered gradually. Brain MRI showed the remained lesion with the longest diameter of 29mm (Figure 1D) and the serum EBV DNA load in the blood reduced to an undetectable level. After radiotherapy, the patient achieved partial response (PR) and his condition was stable, but there were still residual intracranial lesions. The patient refused further systemic chemotherapy. Considering the therapeutic activity of bruton tyrosine kinase (BTK) inhibitors for CNS lymphomas, the patient was administered oral zanubrutinib 80 mg daily (given the concurrent administration of posaconazole for preventing fungal infection) on day +382. He developed transient systemic migrating muscle soreness on the first day during zanubrutinib therapy, which was ameliorated 1 day after discontinuation of the drug. Oral administration of zanubrutinib was subsequently continued without any other side-effects. Blood counts were monitored regularly; the lowest WBC count was 2.9 x 10⁹/L, and the hemoglobin and platelet counts were within the normal range. After starting zanubrutinib, His dizziness and headache had resolved, and the findings of neurological examination were normal. The serum EBV-DNA loads remained negative during the treatment of zanubrutinib. Follow-up brain MRI revealed that the
lesion’s size decreased to 24 x 24 x 21 mm (Figure 1E) with a response of PR. Until the last follow-up in February 2021 (day +516), he was alive without clinical symptom and continued to take zanubrutinib. The treatment process and changes of serum EBV-DNA titer are summarized in Figure 4.

DISCUSSION

To date, there has been no definite guideline or consensus for the optimal treatment for CNS-PTLD after HSCT. The available therapeutic options include the withdrawal of immunosuppressive agents, high-dose MTX and cytarabine, WBRT and adoptive immunotherapy with EBV-specific cytotoxic T lymphocytes (2, 3). Although the patient achieved a PR with significant improvement of clinical symptoms after chemotherapy+ rituximab and WBRT, his headache remained, and MRI showed apparent residual lesions. Subsequent systemic chemotherapy was not considered because the patient refused chemotherapy. EBV-specific cytotoxic T lymphocytes (CTLs) derived from EBV-seropositive transplantation donors or the third party is effective in treating EBV-induced lymphoproliferative diseases through attacking EBV-infected cells, with durable response (4). Doubrovina et al. reviewed 19 EBV-PTLD patients who received...
FIGURE 2 | Single-voxel 1H-magnetic resonance spectroscopy of the tumor area in the left thalamus showing elevated Cho peak in 3.2 ppm and Lip peak in 1.3 ppm with decreased NAA in 2.0 ppm, with corresponding short echo time spectra (A, TE=35ms) and long echo time spectra (B, TE=144ms). Cho, choline compounds; Lip, lipid; NAA, N-acetyl-aspartate.

FIGURE 3 | Photomicrographs of the brain biopsy demonstrating a monomorphic diffuse large B-cell lymphoma with EBV infection. [hematoxylin and eosin (H&E) stain; original magnification (A) ×50; (B) ×200]. Immunohistochemical stains showed that the infiltrating lymphocytes were positive for CD20 (C). EBV-encoded RNA in situ hybridization was positive in the infiltrating cells (D).
EBV-specific CTL infusion after HSCT; in this study, 13 patients (85%) achieved CR and GVHD didn’t occur in any patients (5). However, EBV-specific CTLs was unavailable in our center.

BTK, which is a tyrosine-protein kinase, is critical to B-cell maturation and proliferation, has emerged as a significant therapeutic target for various B-cell malignancies (6, 7). The first-generation BTK inhibitor ibrutinib has shown promising results for CNS lymphoma (8, 9). A phase I clinical trial conducted by Grommes et al. reported that ibrutinib showed a 77% (10/13) clinical response in patients with relapsed or refractory CNS lymphoma, including CR and partial response in 5 patients each (9). Zanubrutinib (BGB-3111), a highly-specific, irreversible second generation BTK inhibitor developed in China, has greater selectivity and higher anti-tumor activity for BTK compared to ibrutinib. It shows more restricted off-target activity for a series of kinases, such as interleukin-2-induced kinases (ITK), Scr family kinases, and epidermal growth factor receptor (EGFR), thereby limiting the toxicity and side-effects (10). It has been approved for relapsed/refractory mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. Moreover, its utility for the treatment of other B-cell malignancies is also being investigated worldwide. In our case, a further decrease in the size of lesions was observed 3 months after the use of zanubrutinib, suggesting its efficacy in treating CNS PTLD. The drug is well-tolerated, and no obvious hematological toxicity or infection was observed during the period of treatment. The patient should take zanubrutinib consistently until treatment failure or the occurrence of unacceptable toxicities. To the best of our knowledge, this was the first report to describe treatment of CNS-PTLD with zanubrutinib. However, it is not sure whether the response of zanubrutinib for PTLD is durable or further improved. Longer follow-up is needed to evaluate its effect.

CONCLUSION

Our case shows that the novel BTK inhibitor zanubrutinib exhibit specific activity for CNS lymphomas. It provides a potential therapeutic option for CNS-PTLD when other attempted measures are judged to be ineffective or inappropriate.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the ethics review committee of the First Affiliated Hospital of Zhejiang University School of Medicine. The
patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

T-TY wrote the manuscript. W-HC, Y-MZ, H-RF and HH contributed to the patient’s medical care. J-MS edited and approved the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was funded by the National Natural Science Foundation of China (Grant no. 82070179).

**REFERENCES**

1. Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma (2019) 60 (1):142–50. doi: 10.1080/10428194.2018.1474462
2. Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders. Cancer Treat Res (2015) 165:305–27. doi: 10.1007/978-3-319-13150-4_13
3. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica (2016) 101 (7):803–11. doi: 10.3324/haematol.2016.144428
4. Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. J Hematol Oncol (2019) 12(1):13. doi: 10.1186/s13045-019-0701-1
5. Doubléovina E, Ofllaz-Soumen B, Ptrockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, et al. Bruton tyrosine kinase inhibitor ibritinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Blood (2012) 119(11):2644–56. doi: 10.1182/blood-2011-08-371971
6. Advani RH, Buggy JJ, Sharrman JP, Smith SM, Boyd TE, Grant B, et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. J Clin Oncol (2013) 31(1):88–94. doi: 10.1200/ JCO.2012.42.7906
7. Honigberg LA, Smith AM, Sirisawad M, Verber E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA (2010) 107(29):13075–80. doi: 10.1073/pnas.1004594107
8. Lionakis MS, Dunlevy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell (2017) 31(6):833–43.e5. doi: 10.1016/j.ccell.2017.04.012
9. Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery (2017) 7(9):1018–29. doi: 10.1158/2159-8290.CD-17-0613
10. Guo YH, Liu Y, Hu N, Yu DS, Zhou CY, Shi GY, et al. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. Journal of Medicinal Chemistry. J Med Chem (2019) 62(17):7923–40. doi: 10.1021/acs.jmedchem.9b00687

**CONFlict OF INTEREST:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Chen, Zhao, Fu, Huang and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.